Durable anti-VEGF and the injection burden problem
Longer-acting anti-VEGF agents are reframing how routine retinal-disease maintenance gets delivered.
Anti-VEGF therapy works. The clinical issue has long been adherence to a monthly-injection cadence that the system cannot operationally sustain. Longer-acting agents are reframing that picture - the question is whether real-world durability matches trial durability.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- ExplainedWhat is presbyopia?
- SnapshotPresbyopia therapy reference (2026)
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.